肝癌患者血清糖链抗原50的检测及其诊断价值

目的 探讨血清糖链抗原50（CA50）对肝癌的诊断及其作为肿瘤标志物的临床诊断价值。方法 选择良、恶性肝病为研究对象，检测慢性肝炎、肝硬化及肝癌患者血清CA50含量，并与肝功能及血清AFP含量进行比较。结果 以正常对照组值＋2标准差为标准，乙型肝炎患者血清CA50阳性者占50％，其中肝硬化患者CA50阳性者占67．7％，原发性肝癌患者占95．1％。而36例血清AFP＜200ug/L的原发性肝癌患者有32例CA50阳性（88．9％）。结论 血清CA50检测能提高AFP浓度升高不明显或AFP阴性的肝癌患者的诊断率；检测血清CA50含量作为诊断肝癌及其它恶性肿瘤的标志物时应考虑慢性良性肝病的假阳性。

Study on the Diagnosis Value of Detection of Serum CA50 Levels in Patients with Hepatocarcinoma

Objective To study the diagnosis values of detection of serum carbongydrate antigen 50 (CA50) levels in patients with malignant trmors. Methods Serum concentrations of CA50 and its relationship with AFP and ALT were simultaneously investigated in patients with chronic non-malignant diseases of the liver and primary hepatocarcinoma(PHC). Result The positivity rates of serum CA50 were as follow: 50% in chronic hepatitis; 67.7% in liver cirrhosis(LC); 95.1% in PHC and 88.9% in AFP negative patients with PHC. Conclusion Detection of serum CA50 are of certain value for clinical diagnosis of AFP negative patients with PHC. The false positivity rates of chronic benign liver diseases should be paid attention wheh serum concentrations of CA50 were used as a valuable marker in patients with PHC or other malignant tumors.